2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1755

Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States
Abstract Number: 1756

Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1757

An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1758

A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1759

Eosinophilic Granulomatosis with Polyangiitis: A Monocentric Cohort Analysis of Manifestations and Relapses of ANCA-Positive and ANCA-Negative Patients
Abstract Number: 1760

Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis
Abstract Number: 1761

Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis
Abstract Number: 1762

Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis
Abstract Number: 1763

Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Abstract Number: 1764

The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Abstract Number: 1765

Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Abstract Number: 1766

Abdominal Adipose Tissue Predicts Incident Major Cardiovascular Events in Systemic Necrotizing Vasculitis Patients: Data from a Prospective Cohort Study on 120 Patients
Abstract Number: 1767

Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis
Abstract Number: 1768

Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Abstract Number: 1769

Efficacy and Safety of Biomimic Rituximab in Granulomatosis with Polyangiitis – Experience from a Single Tertiary Care Centre in India

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].